Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Chang Hao Tsao, Simon ^a,b   Weiss, Jonathan ^a   Hudson, Christopher ^a,c   Christophi, Christopher ^b   Cebon, Jonathan ^a,b,c   Behren, Andreas ^a,b,c   Dobrovic, Alexander ^a,b,c  

^a OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c LA TROBE UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DNA; LACTATE DEHYDROGENASE;

BLOOD; FEMALE; GENETICS; HUMAN; LONGITUDINAL STUDY; MALE; MELANOMA; METASTASIS; MUTATION; ONCOGENE RAS; POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TUMOR CELL LINE; X-RAY COMPUTED TOMOGRAPHY;

CELL LINE, TUMOR; DNA, NEOPLASM; FEMALE; GENES, RAS; HUMANS; LACTATE DEHYDROGENASES; LONGITUDINAL STUDIES; MALE; MELANOMA; MUTATION; NEOPLASM METASTASIS; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS B-RAF; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84934985499     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep11198     Document Type: Article

References (23)

1. Rigel, D. S., Russak, J. & Friedman, R. The Evolution of Melanoma Diagnosis: 25 Years Beyond the ABCDs. CA: A Cancer Journal for Clinicians 60, 301-316 (2010).
2. Australian Institute of Health and Welfare (AIHW) - Australian Government. Cancer in Australia: an overview 2012. Cancer series no. 74. Cat. no. CAN 70. Canberra: AIHW 1-215 (2012).
3. Balch, C. M. et al. Final Version of 2009 AJCC Melanoma Staging and Classification. Journal of Clinical Oncology 27, 6199-6206 (2009).
4. Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal of Cancer 45, 228-247 (2009).
5. Bettegowda, C. et al. Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. Science Translational Medicine 6, 224ra24-224ra24 (2014).
6. van der Vaart, M. & Pretorius, P. J. Circulating DNA, its origin and fluctuation. Annals of the New York Academy of Sciences 1137, 18-26 (2008).
7. Goebel, G., Zitt, M., Zitt, M. & Muller, H. M. Circulating nucleic acids in plasma or serum (CNAPS) as prognostic and predictive markers in patients with solid neoplasias. Dis Markers 21, 105-120 (2005).
8. Fleischhacker, M. & Schmidt, B. Circulating nucleic acids (CNAs) and cancer-A survey. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1775, 181-232 (2007).
9. Dawson, S.-J. et al. Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer. N Engl J Med 368, 1199-1209 (2013).
10. Diehl, F. et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 14, 985-990 (2007).
11. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002).
12. Sensi, M. et al. Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma. Oncogene 25, 3357-3364 (2006).
13. Ascierto, P. A. et al. Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma. Journal of Clinical Oncology 31, 3205-3211 (2013).
14. Lipson, E. J. et al. Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. Journal for Immunotherapy of Cancer 2, 42-7 (2014).
15. Jennings, L. J., George, D., Czech, J., Yu, M. & Joseph, L. Detection and quantification of BCR-ABL1 fusion transcripts by droplet digital PCR. J Mol Diagn 16, 174-179 (2014).
16. Behren, A. et al. The Ludwig institute for cancer research Melbourne melanoma cell line panel. Pigment Cell Melanoma Res 26, 597-600 (2013).
17. Oxnard, G. R. et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative nextgeneration genotyping of cell-free plasma DNA. Clin Cancer Res 20, 1698-1705 (2014).
18. Hamid, O. et al. Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma. N Engl J Med 369, 134-144 (2013).
19. McDermott, D. et al. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treatment Reviews 40, 1056-1064 (2014).
20. Wolchok, J. D. et al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria. Clinical Cancer Research 15, 7412-7420 (2009).
21. Gogas, H. et al. Biomarkers in melanoma. Annals of Oncology 20, vi8-vi13 (2009).
22. Sanmamed, M. F. et al. Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors. Clinical Chemistry 61, 297-304 (2015).
23. Wu, J., Rosenbaum, E., Begum, S. & Westra, W. H. Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis. Am J Dermatopathol 29, 534-537 (2007).